CoChat

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Estimating progression-free survival (PFS) and overall survival superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier end point surrogates that are predictive of long-term clinical benefit. Minimal residual disease (MRD)-negativity is a common intermediate end point that has shown prognostic value for clinical benefit in MM. This meta-analysis was based on the US Food and Drug Administration guidance for considerations for a meta-analysis of MRD as a clinical end point and evaluates MRD-negativity as an early end point reasonably likely to predict long-term clinical benefit. Eligible studies were phase 2 or 3 randomized controlled clinical trials measuring MRD-negativity as an end point in patients with MM, with follow-up of ≥6 months following an a priori–defined time point of 12 ± 3 months after randomization. Eight newly diagnosed MM studies evaluating 4907 patients were included. Trial-level associations between MRD-negativity and PFS were R2WLSiv, 0.67 (95% confidence interval [CI], 0.43-0.91) and R2copula 0.84 (0.64 to >0.99) at the 12-month time point. The individual-level association between 12-month MRD-negativity and PFS resulted in a global odds ratio (OR) of 4.02 (95% CI, 2.57-5.46). For relapse/refractory MM, there were 4 studies included, and the individual-level association between 12-month MRD-negativity and PFS resulted in a global OR of 7.67 (4.24-11.10). A clinical trial demonstrating a treatment effect on MRD is reasonably likely to eventually demonstrate a treatment effect on PFS, suggesting that MRD may be an early clinical end point reasonably likely to predict clinical benefit in MM, that may be used to support accelerated approval and thereby, expedite the availability of new drugs to patients with MM.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.2024024371

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Abrams Kaplan, 2022, Multiple myeloma: top 10 advances in the past 10 years, Target Ther Oncol, 11, 70

Cited by

See all 131

Metadata

Authors
Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., Mellqvist, U.-H., McFadden, I., Oprea, C., Ross, J. A., Talpes, M., Hydren, J. R., Ahlstrom, J. M., Kazandjian, D., Weinhold, N., Zhang, R., Stetler-Stevenson, M., Marti, G., & Devlin, S. M.
Affiliations
  • University of Miami (US)
  • Janssen Research & Development (United States) (US)
  • AbbVie (United States) (US)
  • 4Takeda, Lexington, MA
  • Universitätsklinikum Würzburg (DE)
  • University Hospital Heidelberg (DE)
  • Nuremberg Hospital (DE)
  • Takeda (United States) (US)
  • Södra Älvsborg Hospital (SE)
  • Amgen (United States) (US)
  • Sanofi (France) (FR)
  • 11HealthTree Foundation, Lehi, UT
  • Heidelberg University (DE)
  • 12National Cancer Institute, National Institutes of Health, Bethesda, MD
  • National Institutes of Health (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Landgren, Ola
Venue
Blood
Published
2024-07-25
Volume
144
Issue
4
Pages
359-367
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4398143893
Cited by
131
References
29
Citations by year
2026: 47 · 2025: 69 · 2024: 15
FWCI
10.39
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA008748, P30CA240139)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, minimal residual disease, MRD negativity, progression-free survival, surrogate endpoints, accelerated approval, newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, treatment response prediction
MeSH terms
Progression-Free Survival, Humans, Multiple Myeloma, Prognosis, Randomized Controlled Trials as Topic, Neoplasm, Residual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. https://app.cochat.ai/papers/10.1182/blood.2024024371
The paper
Landgren, O., Prior, T. J., Masterson, T., Heuck, C., Bueno, O. F., Dash, A. B., Einsele, H., Goldschmidt, H., Knop, S., Li, C., Mellqvist, U.-H., McFadden, I., Oprea, C., Ross, J. A., Talpes, M., Hydren, J. R., Ahlstrom, J. M., Kazandjian, D., Weinhold, N., . . . Devlin, S. M. (2024). EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. https://doi.org/10.1182/blood.2024024371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.